-
1.发明申请PPS for the prevention of potential adverse effects caused by CD3 specific binding domains 有权PPS用于预防CD3特异性结合结构域引起的潜在不良反应公开(公告)号：US20140228316A1
公开(公告)日：2014-08-14
申请号：US14176089
申请日：2014-02-08
发明人： Peter Kufer , Dirk Nagorsen , Juergen Scheele , Gerhard Zugmaier , Matthias Klinger , Patrick Hoffmann , Virginie Naegele , Elaine-Pashupati Dopfer
IPC分类号： A61K31/737
CPC分类号： A61K31/737
摘要： The present invention relates to a PPS for use in the amelioration, treatment or prophylaxis of neurological adverse events caused by a CD3 binding domain. Kits comprising a PPS, a CD3 binding domain and instructions for use which indicate that the PPS is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
摘要翻译： 本发明涉及用于改善，治疗或预防由CD3结合结构域引起的神经不良事件的PPS。 还公开了包含PPS，CD3结合结构域的试剂盒和用于指示PPS用于治疗由所述CD3结合结构域引起的神经功能不良事件的改善和/或预防的使用说明书。
-
公开(公告)号：US20170275373A1
公开(公告)日：2017-09-28
申请号：US15329668
申请日：2015-07-31
发明人： Peter Kufer , Patrick Hoffmann , Markus Münz , Matthias Klinger , Elaine-Pashupati Dopfer , Elisabeth Nahrwold
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/18 , C07K16/2803 , C07K16/2809 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2319/31
摘要： The present invention provides to a bispecific single chain antibody construct binding to a target cell surface antigen via a first binding domain and to the T cell surface antigen CD3 via a second binding domain, the construct comprising two FcRn binding peptides. Moreover, the invention provides a nucleic acid molecule encoding the antibody construct, a vector comprising said nucleic acid molecule and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
-
公开(公告)号：US09688760B2
公开(公告)日：2017-06-27
申请号：US14176091
申请日：2014-02-08
发明人： Peter Kufer , Dirk Nagorsen , Juergen Scheele , Gerhard Zugmaier , Matthias Klinger , Patrick Hoffmann , Virginie Naegele , Elaine-Pashupati Dopfer
IPC分类号： C07H21/04 , C07C43/00 , C07C49/00 , C07C237/26 , C07C331/00 , C12P21/08 , A01N37/18 , A61K31/65 , A01N31/00 , A61K31/095 , G01N33/00 , C12N5/071 , C07K16/28 , A61K31/10 , A61K39/395 , C07K16/18 , G01N33/50 , A61K39/00
CPC分类号： C07K16/2809 , A61K31/10 , A61K31/65 , A61K39/3955 , C07K16/18 , C07K2317/70 , G01N33/5008 , G01N2500/04
摘要： The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20×CD3 or a CD19×CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment. Such anti-adhesive type compounds include, but are not limited to, antibodies, like natalizumab, efalizumab, and etrolizumab; minocycline, (acetyl-)salicyclic acid, astilbin, and flavonoids; and thrombin and pentosanpolysulfate (PPS), or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11084876B2
公开(公告)日：2021-08-10
申请号：US15604341
申请日：2017-05-24
发明人： Peter Kufer , Dirk Nagorsen , Juergen Scheele , Gerhard Zugmaier , Matthias Klinger , Patrick Hoffmann , Virginie Naegele , Elaine-Pashupati Dopfer
摘要： The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
-
5.发明授权PPS for the prevention of potential adverse effects caused by CD3 specific binding domains 有权PPS用于预防CD3特异性结合结构域引起的潜在不良反应公开(公告)号：US09486475B2
公开(公告)日：2016-11-08
申请号：US14176089
申请日：2014-02-08
发明人： Peter Kufer , Dirk Nagorsen , Juergen Scheele , Gerhard Zugmaier , Matthias Klinger , Patrick Hoffmann , Virginie Naegele , Elaine-Pashupati Dopfer
IPC分类号： A01N43/04 , A61K31/715 , A61K31/737
CPC分类号： A61K31/737
摘要： The present invention relates to a pentosanpolysulfate (PPS) or a pharmaceutically acceptable salt thereof for use in the amelioration, treatment, or prevention of adverse neurological events caused by administering an antibody or fragment thereof comprising a CD3 binding domain, including a CD19 x CD3 bispecific single chain antibody, such as blinatumomab. PPS is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. Kits comprising a PPS, an antibody or fragment thereof comprising a CD3 binding domain, and instructions for administration, which indicate that the PPS is to be employed for the amelioration, treatment or prevention of adverse neurological events caused by administering the antibody or fragment thereof comprising said CD3 binding domain, are also disclosed.
摘要翻译： 本发明涉及一种戊糖聚硫酸酯（PPS）或其药学上可接受的盐，用于改善，治疗或预防由施用包含CD3结合结构域的抗体或其片段引起的不良神经系统事件，包括CD19×CD3双特异性 单链抗体，如blinatumomab。 PPS是半合成生产的肝素样大分子碳水化合物衍生物，其化学和结构上类似于糖胺聚糖。 包含PPS，抗体或其片段的试剂盒，其包含CD3结合结构域和给药指示，其指示PPS用于改善，治疗或预防由施用抗体或其片段引起的不良神经系统事件，所述抗体或片段包含 所述CD3结合结构域也被公开。
-
6.发明申请公开(公告)号：US20170327581A1
公开(公告)日：2017-11-16
申请号：US15604341
申请日：2017-05-24
发明人： Peter Kufer , Dirk Nagorsen , Juergen Scheele , Gerhard Zugmaier , Matthias Klinger , Patrick Hoffmann , Virginie Naegele , Elaine-Pashupati Dopfer
摘要： The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
-
7.发明申请Anti-Leukocyte Adhesion for the Mitigation of Potential Adverse Events caused by CD3-Specific Binding Domains 有权用于缓解CD3特异性结合域引起的潜在不良事件的抗白细胞粘附公开(公告)号：US20140227272A1
公开(公告)日：2014-08-14
申请号：US14176091
申请日：2014-02-08
发明人： Peter Kufer , Dirk Nagorsen , Juergen Scheele , Gerhard Zugmaier , Matthias Klinger , Patrick Hoffmann , Virginie Naegele , Elaine-Pashupati Dopfer
CPC分类号： C07K16/2809 , A61K31/10 , A61K31/65 , A61K39/3955 , C07K16/18 , C07K2317/70 , G01N33/5008 , G01N2500/04
摘要： The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
摘要翻译： 本发明本质上涉及降低或抑制哺乳动物T细胞与哺乳动物内皮细胞结合的化合物，以用于预防和/或改善和/或治疗由治疗引起的临床不良事件的方法，所述方法包括： 将T细胞导向患者的靶细胞。 也可以考虑治疗具有或处于由治疗引起的临床不良事件风险的患者的方法，其包括将T细胞重新导向靶细胞。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.019 秒)
